Literature DB >> 31668247

Andexanet Response.

Truman J Milling1, Stuart Connolly2.   

Abstract

Entities:  

Year:  2019        PMID： 31668247      PMCID： PMC7375707          DOI： 10.1016/j.annemergmed.2019.05.033

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN： 0196-0644            Impact factor:   5.721


× No keyword cloud information.
  10 in total

1.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.

Authors:  Raphael Marlu; Enkelejda Hodaj; Adeline Paris; Pierre Albaladejo; Jean Luc Cracowski; Jean Luc Crackowski; Gilles Pernod
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

2.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

3.  A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

Authors:  Stephan Glund; Viktoria Moschetti; Stephen Norris; Joachim Stangier; Michael Schmohl; Joanne van Ryn; Benjamin Lang; Steven Ramael; Paul Reilly
Journal:  Thromb Haemost       Date:  2015-03-19       Impact factor: 5.249

4.  Adventures With Andexanet Alfa in Efficacy, Effectiveness, and One-Armed Studies: May 2019 Annals of Emergency Medicine Journal Club.

Authors:  Ryan P Radecki; Rory J Spiegel
Journal:  Ann Emerg Med       Date:  2019-05       Impact factor: 5.721

5.  Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

Authors:  Ammar Majeed; Anna Ågren; Margareta Holmström; Maria Bruzelius; Roza Chaireti; Jacob Odeberg; Eva-Lotta Hempel; Maria Magnusson; Tony Frisk; Sam Schulman
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

6.  Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.

Authors:  Sam Schulman; Peter L Gross; Bruce Ritchie; Susan Nahirniak; Yulia Lin; Lani Lieberman; Marc Carrier; Mark A Crowther; Indy Ghosh; Alejandro Lazo-Langner; Michelle Zondag
Journal:  Thromb Haemost       Date:  2018-03-21       Impact factor: 5.249

7.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

8.  Preclinical safety and efficacy of andexanet alfa in animal models.

Authors:  G Lu; S J Hollenbach; D C Baker; S Tan; A Hutchaleelaha; J T Curnutte; P B Conley
Journal:  J Thromb Haemost       Date:  2017-08-05       Impact factor: 5.824

9.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

10.  Novel oral anticoagulants and reversal agents: Considerations for clinical development.

Authors:  Troy C Sarich; Jonathan H Seltzer; Scott D Berkowitz; James Costin'; John T Curnutte; C Michael Gibson; Maureane Hoffman; Edvardas Kaminskas; Mitchell W Krucoff; Jerrold H Levy; Paul D Mintz; Paul A Reilly; Philip T Sager; Daniel E Singer; Norman Stockbridge; Jeffrey I Weitz; Peter R Kowey
Journal:  Am Heart J       Date:  2015-03-26       Impact factor: 4.749
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.